Vanguard FTSE Developed Europe All Cap Index ETF | VERegister to Unlock Ratings |
Performance History | 29/02/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 1.6 | 17.7 | -5.6 | 13.1 | 1.7 | |
+/-Cat | -1.7 | 1.7 | 3.5 | -0.7 | 0.0 | |
+/-B’mrk | -1.7 | -0.1 | 1.8 | -0.5 | -0.2 | |
Category: European Equity | ||||||
Category Benchmark: Morningstar Eur GR CAD |
Key Stats | ||
Closing Price 31/03/2024 | CAD 35.35 | |
Day Change | - | |
Morningstar Category™ | European Equity | |
Volume | 659 | |
Exchange | TORONTO STOCK EXCHANGE | |
ISIN | CA92206M1005 | |
Fund Size (Mil) 28/03/2024 | CAD 180.16 | |
Share Class Size (Mil) 28/03/2024 | CAD 180.16 | |
Ongoing Charge - | -% |
Investment Objective: Vanguard FTSE Developed Europe All Cap Index ETF | VE |
The fund seeks to track, to the extent reasonably possible and before fees and expenses, the performance of a broad European equity index that focuses on developed European markets. Currently, this Vanguard ETF seeks to track the FTSE Developed Europe All Cap Index (or any successor thereto). It invests directly or indirectly primarily in large-, mid- and small-capitalization stocks of companies located in developed European markets. |
Returns | ||||||||||||||||
|
Management | ||
Manager Name Start Date | ||
Not Disclosed 30/06/2014 | ||
Inception Date 30/06/2014 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
FTSE Developed Europe All Cap TR CAD | Morningstar Eur GR CAD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Vanguard FTSE Developed Europe All Cap Index ETF | VE | 29/02/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk A/S Class B | Healthcare | 3.10 |
ASML Holding NV | Technology | 3.09 |
Nestle SA | Consumer Defensive | 2.32 |
Lvmh Moet Hennessy Louis Vuitton SE | Consumer Cyclical | 1.88 |
Novartis AG Registered Shares | Healthcare | 1.75 |
Increase Decrease New since last portfolio | ||
Vanguard FTSE Developed Europe All Cap Index ETF | VE |